ArticleDrug design, development and therapy2025
Elucidating the Pharmacological Basis of Xianling Cifang Granules Against Breast Cancer. A Metabolomic Profiling Study.
Article in Drug design, development and therapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Regulatory effects of traditional Chinese medicine on the breast-cancer immune microenvironment.Frontiers in immunology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To analyze the constituents and metabolic products of Xianling Cifang Granules (XLCF) in the serum of mice. The potential targets of XLCF in the treatment of breast cancer (BC) were explored by combining network pharmacology and molecular docking technology. Methods: Serum was collected from mice following oral administration of XLCF and analyzed using UHPLC-Q Exactive Orbitrap-MS. Absorbed prototype constituents and metabolites were identified by comparing retention times, accurate masses, MS/MS fragments, and isotopic patterns. Network pharmacology predicted potential therapeutic targets, and molecular docking (Autodock/Pymol) validated interactions between key constituents and targets. Results: Our comprehensive metabolomic profiling elucidates the pharmacological basis of XLCF against BC by identifying its absorbed constituents and their potential therapeutic links. It identified 122 prototype constituents of XLCF entering the systemic circulation. Icaritin (a metabolite derived from Conclusion: This integrated approach delineates the anti-BC mechanism of XLCF, 122 absorbed constituents (with Icaritin as key) and 62 altered metabolites drive systemic metabolic reprogramming, acting through ADORA1, AKR1B1 and ADORA3 targets to modulate critical pathways. These findings provide robust pharmacological evidence supporting the clinical application of XLCF against BC and demonstrate the value of combining metabolomics with target prediction for Traditional Chinese Medicine (TCM) research. Experimental validation of the identified targets is warranted.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.